by ltsiwpadmin | May 29, 2017 | News
Medical News Bulletin May 29, 2017 Fatty liver disease commonly affects alcoholics and those who are overweight or diabetic. There are currently no treatments for this disease, aside from recommendations to exercise and make lifestyle changes. A recent review article...
by ltsiwpadmin | May 26, 2017 | Policy & Public Affairs, Publications
Abstract BACKGROUND & AIMS Lean nonalcoholic fatty liver disease (NAFLD) is defined as NAFLD that develops in patients with a body mass index (BMI) less than 25 kg/m2. We investigated the differences between lean NAFLD and NAFLD in overweight and obese persons,...
by ltsiwpadmin | May 26, 2017 | News
Source: The Life Sciences Report May 26, 2017 (Investorideas.com Newswire) NASH is an epidemic in the U.S., with more than 100 million people believed to be affected. Yet no FDA-approved treatments are available, with the exception of liver transplantation for...
by ltsiwpadmin | May 23, 2017 | Diagnostics & Therapeutic Advancements, Publications
Abstract Ligand-activated nuclear receptors, including peroxisome proliferator-activated receptor alpha (PPARα), pregnane X receptor, and constitutive androstane receptor, were first identified as key regulators of the responses against chemical toxicants. However,...
by ltsiwpadmin | May 22, 2017 | Prevention & Management, Publications
Abstract Lifestyle intervention can be effective when treating non-alcoholic fatty liver diseases (NAFLD) patients. Weight loss decreases cardiovascular and diabetes risk and can also regress liver disease. Weight reductions of ⩾10% can induce a near universal...
Recent Comments